The Weekly Recap 5/15/26: LSI Alumni Achievements Driving Medtech and Healthtech Forward

In a successful week for the medical technology companies in the LSI Alumni community, we saw LSI Alumni receive new funding, launch partnerships, receive regulatory approvals, and much more on the road to LSI Asia ‘26 in Singapore (June 30 - July 2).

Adialante

Granted its second U.S. patent covering the core technology behind its ability to image in MRIs using radio waves. The company is developing a new class of mobile MRI systems designed to deliver diagnostic-quality imaging directly to practices without the need for construction or major capital investment.

Angelini Ventures

Welcomed Samantha Wong, PhD, as Investment Analyst. Dr. Wong played a key role in the launch of EspressoLab by Angelini Ventures and the establishment of the company’s Singapore office.

Apreo Health

Announced the appointment of LSI Alumni David Amerson to its Board of Directors and a strategic investment from OSF Ventures, the corporate investment arm of OSF HealthCare. Amerson has over 30 years of leadership in the medical device industry, most recently serving as President of Interventional Urology at Teleflex following its $1.1B acquisition of NeoTract, where he was President and CEO.

BlueWind Medical

Closed $47.8M in financing in a combination of equity and debt. The company plans to use the proceeds to fund further commercialization for its Revi® System, an implantable tibial neuromodulation platform that treats urgency urinary incontinence. 

Brainomix

Announced an expansion of its partnership with Boehringer Ingelheim to improve the care of patients with progressive pulmonary fibrosis. Building on results from the REVISE PPF study, the next phase, PROGRESS PPF, a prospective multicenter study, will focus on generating evidence of e-Lung’s clinical impact at scale, with deployments of e-Lung planned at numerous sites across the U.S.

Butterfly Medical

Closed a $21M upsized Series C fundraising round, including participation from the European Innovation Council (EIC), Junson Capital, MedVenture, and New Rhein Healthcare Investors. The company's flagship product, the Butterfly® Medical device, is designed to restore natural urinary flow to provide significant, long-term relief from benign prostatic hyperplasia symptoms, thereby improving patients' quality of life.

Canary Medical

Granted FDA BDD for its Canary Revision Tibial Extension. The system is designed to provide clinicians with autonomous kinematic data following TKA revision procedures, supporting earlier identification of recovery concerns and more informed postoperative management decisions.

CustomSurg

Appointed Richard Keiser as its CTO. Keiser has over a decade of experience in medtech managing and directing software platforms and infrastructure, and looks to help the company advance its OrthoPlanner™, an FDA-cleared solution for pre-operative fracture planning. 

EndoShunt Medical

Welcomed LSI Alumni Catherine Kiani as a Board Observer on behalf of Elderberry Ventures. Kiani, backed by an involved advisory team with four decades of experience building, scaling, and defending medical device companies, brings a rare combination of legal, governance, and medical technology expertise. 

Endospan

Acquired by Artivion for an upfront purchase price of $135M. The acquisition comes on the heels of FDA approval for its NEXUS Aortic Arch Stent Graft, which was supported by the one-year results of the prospective multicenter TRIOMPHE investigational device exemption study. 

HeartBeam

Entered into an agreement with Atelier Health to expand its commercial footprint into Southern California. Combined with its recent partnership with ClearCardio, the partnership with Atelier establishes the company’s initial presence across Southern California, the New York metro, Dallas, and South Florida, creating a foundation for broader national growth.

This blog is originally published here: https://www.lifesciencemarketresearch.com/insights/the-weekly-recap-51526-lsi-alumni-achievements-driving-medtech-and-healthtech-forward

Comments

Post a Comment

Popular posts from this blog

Cover Story: A Page from Ray Cohen’s Playbook: Scaling, Exiting, and Winning in Medtech

With four decades of company-building, IPOs, boardroom leadership, and monumental exits behind him, Raymond W. Cohen has become one of medtech’s most successful operators. But behind the financial wins — including the recent back-to-back $3.7 billion Axonics and $600 million SoniVie acquisitions by Boston Scientific — is a deeper story of Cohen’s contrarian, full-transparency, people-centered, no-BS approach to leadership and strategy. “People crave inspired, authentic, and transparent leadership that thinks big and acts boldly. They want to be enrolled in a vision of what is possible, and be recognized and compensated for creating measurable results, not be fed a bunch of platitudes.” A quote that is classic  Ray Cohen  — blunt, unapologetic, no-nonsense, and grounded in hard-won experience. With more than four decades in medtech, Cohen has done what many aspire to — build, lead, scale, and sell high-stakes, successful ventures with precision and zero fluff. Known for his no-...
Read more

The Weekly Recap 6/13/25: LSI Alumni Achievements Driving Medtech and Healthtech Forward

In a successful week for the medical technology companies in the LSI Alumni community, we saw LSI Alumni secure over $63M in new funds, receive FDA 510(k) clearances, announce an acquisition, and much more as we wind down   LSI Asia  ’25 in Singapore and gear up for  LSI Europe  ’25 in London (September 7–11). Accelus Received FDA 510(k) clearance for the FlareHawk Interbody Fusion System to be safely subjected to MRI scanning in certain conditions. The clearance supports Accelus’s commitment to safe, high-performance spinal solutions and expands imaging options for patients with FlareHawk implants. Aortyx Raised $16M to advance its bioresorbable aortic patch toward first-in-human trials. The funding supports continued development of Aortyx’s minimally invasive, tissue-regenerating solution for aortic dissection and positions the company for clinical entry within two years. Atraverse Medical Closed $29.4M in follow-on financing to scale U.S. commercialization of HOTW...
Read more

Microbot Medical and the Endovascular Robotics Opportunity Taking Shape

In November, Microbot Medical reached a meaningful milestone in the evolution of endovascular robotics, announcing that Emory University Hospital in Atlanta has become the first hospital worldwide to use the company’s LIBERTY system for patient care. Microbot is currently operating under a limited commercial release following FDA clearance, with a broader market launch planned for April 2026 at the Society of Interventional Radiology conference. While still early, the move signals growing confidence that robotic assistance inside the vasculature is beginning to transition from concept to clinical reality. To understand why this matters, it helps to step back and examine the numbers behind the endovascular robotics market and how Microbot’s approach fits into a rapidly evolving competitive landscape. Defining the Endovascular Procedure Landscape Endovascular procedures encompass any intervention performed from within a blood vessel. In practical terms, this includes coronary, periphe...
Read more